Platinum N-Heterocyclic Carbene Complexes Based on Adenosine: Synthesis and Antiproliferative Studies.

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-06-04 DOI:10.1002/cmdc.202500368

Ana Petronilho, Claudia Nunes, Giulia Orsini, Andreia Marinho

引用次数: 0

Abstract

Platinum(II) N-heterocyclic carbene complexes based on 2-chloroadenosine were synthesized. The reaction of 2-chloro-2',3',5'-tri-O-acetyladenosine 1 with Pt(PPh3)4 by C-Cl oxidative addition yielded complex 2, with a PtII centre bonded to the C-2 of the purine ring. Complex 2 was reacted with methyl iodide to yield N-heterocyclic carbene 3, which was subsequently deprotected under basic conditions to provide N-heterocyclic carbene 4, bearing a fully deprotected ribose . The compounds were tested for their cytotoxic activity in five different cell lines: L929, HEK293, A375, MDA-MB-231, and MCF-7. Among the platinum compounds, compound 2, the neutral compound bearing an anionic adenosyl ligand, provides the highest cytotoxic activity, particularly against the A375 and MDA-MB-231 cell lines. Encapsulation of compound 2 with nanostructured lipid carriers does not lead to an improvement on the cytotoxic activity.

查看原文本刊更多论文

基于腺苷的铂n -杂环卡宾配合物：合成及抗增殖研究。

合成了基于2-氯腺苷的铂（II） n -杂环羰基配合物。2-氯-2',3',5'-三- o-乙酰腺苷1与Pt(PPh3)4通过C-Cl氧化加成反应得到配合物2，其PtII中心与嘌呤环的C-2键合。配合物2与碘化甲酯反应生成n -杂环卡宾3，随后在碱性条件下脱保护生成n -杂环卡宾4，携带一个完全脱保护的核糖。在五种不同的细胞系L929、HEK293、A375、MDA-MB-231和MCF-7中测试了这些化合物的细胞毒活性。在铂类化合物中，含有阴离子腺苷配体的中性化合物化合物2具有最高的细胞毒活性，特别是对A375和MDA-MB-231细胞系。用纳米结构脂质载体包封化合物2不会导致细胞毒活性的提高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.